24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Publication dates

Insulin Industry, February 2015 Market Reports from Top Publishers

You might be interested in: medical equipment, drug, drug delivery, therapeutics, protein, diabetes therapeutics, biosimilar, human insulin, insulin delivery, medical, syringe, cartridge, growth hormone, human growth hormone, industrial construction.


 
1-10 of 95 reports for Insulin

Insuline Medical Ltd

Insuline Medical Ltd

  • $ 55
  • Company report
  • January 2015
  • by Wright Investors' Service

... Included for insuline medical ltd are the company description, recent stock performance, profitability analysis, dividend analysis, and key data items (ticker, major industry, sub-industry, fiscal year end ...

Cardiometabolic Drug News JANUARY 2015

Cardiometabolic Drug News JANUARY 2015

  • $ 1 114
  • Industry report
  • January 2015
  • by Espicom Business Intelligence

... To ljpc-501industry brief - lilly/adocia to co-develop biochaperone technology-based ultra-rapid insulinindustry brief - the medicines company/sciclone collaborate for angiomax/cleviprex in china ...

Oral Thin Films Market, 2015 - 2025

Oral Thin Films Market, 2015 - 2025

  • $ 1 899
  • Industry report
  • January 2015
  • by Roots Analysis Private Ltd.

... Influenza vaccine6.8.3. Target population6.8.4. Flu/influenza vaccine sales6.8.5. Oral thin film formulation of flu/influenza vaccine6.9. insulin6.9.1. Overview6.9.2. Dosage forms ...

2015 Deep Research Report on Global Recombinant Human Insulin Industry

2015 Deep Research Report on Global Recombinant Human Insulin Industry

  • $ 2 600
  • Industry report
  • January 2015
  • by QY Research Group

... Recombinant human insulin supply import export consumption 20chapter five recombinant human insulin manufacturing process and cost structure 215.1 Recombinant human insulin product specifications 21 ...

Vildagliptin  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Vildagliptin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Industry report
  • January 2015
  • by Ark Patent Intelligence

... A thiazolidinedione or insulininnovator:novartis (galvus, jalra, icandra, xiliarx, zomarist, eucreas, sobrea, galvumet)country coverage:# australia# canada# france # germany ...

Glimepiride, Pioglitazone  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Glimepiride, Pioglitazone - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Industry report
  • January 2015
  • by Ark Patent Intelligence

... This report covers:international nonproprietary name: glimepiride, pioglitazoneindications: adjunct to diet, exercise and weight loss, to lower the blood glucose, reduce insulin ...

Metformin, Vildagliptin  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Metformin, Vildagliptin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Industry report
  • January 2015
  • by Ark Patent Intelligence

... Or insulininnovator:novartis (galvumet, sobrea, eucreas, icandra, zomarist)country coverage:# australia# canada# france # germany# great britain# italy# japan ...

Autoimmune Drug Focus NOVEMBER 2014

Autoimmune Drug Focus NOVEMBER 2014

  • $ 1 114
  • Industry report
  • November 2014
  • by Espicom Business Intelligence

... Defends european insulin patentsindustry brief - orgenesis approved for european grant in type i diabetes programmeindustry brief - new diamyd diabetes vaccine combination study approved in sweden ...

InsuLine Medical Ltd. - Strategic SWOT Analysis Review

InsuLine Medical Ltd. - Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Of insulin treatments. Its products include insupad and insupatch. insuline medical's insupad is a patch for syringes and insulin pens. The company's insupatch is used as a catheter and pump holder for pumps ...

Physician Views: Will next-generation long-acting insulins prove compelling?

Physician Views: Will next-generation long-acting insulins prove compelling?

  • $ 681
  • Industry report
  • November 2014
  • by Firstword Pharma

... Lantus (Us respondents assume that biosimilar lantus is not rated as interchangeable) physician views: will next-generation long-acting insulins prove compelling ...

About 2 800 reports for Insulin

Download Unlimited Documents from Trusted Public Sources

Novo Nordisk Annual Report 2013

  • January 2013
    116 pages
  • Diabete  

View report >

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.